Company

About CALCIVIS®

CALCIVIS® is focused on modernizing the management of dental demineralization by providing what leading clinicians consider to be the “Holy Grail” of cariology (tooth decay): real-time chair side assessment of the caries disease process.¹

Information about activity of enamel demineralization has not been available previously and enables the preventive dentistry approach.

By supporting early decision making and improving patient communication, compliance with oral health advice increases and consent for prescribed treatment improves leading to enhanced clinical and professional outcomes.²

History

CALCIVIS® was co-founded in 2012 by Adam Christie (CEO) and Bruce Vernon (CTO). From its headquarters in Edinburgh, the CALCIVIS® team combines product development, clinical and commercial expertise. The CALCIVIS® Imaging System was developed with input from leading International specialists in caries and erosion.

Since then multiple preclinical and clinical studies have been undertaken including one pivotal clinical study designed to support our regulatory filing to the FDA leading to it’s approval.

Additionally, the CALCIVIS® Imaging System has the UKCA mark for the UK.

CALCIVIS® is internationally focused and actively forming relationships with leading clinicians and other stakeholders in dental markets around the world.

CALCIVIS Team

Adam Christie,
CEO

Bruce Vernon,
CTO

Dr. John Brown,
Chairman

Steven Valenti,
Executive Management Team

Ronald Frezel,
Vice President of Sales & Marketing

Jill McGregor,
CFO

Alban Gandais,
Advisor

Dr. Chris Longbottom,
Advisor

Peter Rees,
Board

Michael Crane,
Board

Sarah Hardy,
Observer – Board

Veronica Tyrell,
Observer – Board

  1. Douglas et al: Rationale and Evidence for the International Caries Detection and Assessment System (ICDAS II)
  2. Refer to full User Instructions prior to use.